<DOC>
	<DOCNO>NCT01180205</DOCNO>
	<brief_summary>To show superior effect combination Telmisartan Amlodipine ( T A ) v Olmesartan Hydrochlorothiazide ( O HCTZ ) endothelial dysfunction measure flow mediate dilation ( FMD ) hypertensive risk patient beyond bloodpressure BP ( equal BP arm ; target BP &lt; 140/90 mmHg ( &lt; 130/80 mmHg renally impaired and/ diabetic patient ) . To investigate effect T A v O HCTZ reduce arterial stiffness carotid atherosclerotic plaque .</brief_summary>
	<brief_title>Telmisartan , Amlodipine Flow Mediated Dilation</brief_title>
	<detailed_description>This Phase IV , randomise , double-blind , forced- titration , active control , mono-center study primarily compare effect endothelial function combination telmisartan amlodipine versus olmesartan hydrochlorothiazide hypertensive patient risk beyond blood pressure . Additionally , key secondary endpoint trial change plaque intima medium complex echogenicity change arterial stiffness 26 week treatment . 576 patient include study screen period two week randomise one two treatment group . Pretreatment ARBs , ACE-Inhibitors , amlodipine diuretic stop last day visit 2 . At visit 2 treatment either telmisartan amlodipine olmesartan hydrochlorothiazide start , medication stop without replace study medication . After two week treatment patient up-titrated maintenance dose follow 24 week . The trial perform one center Germany access patient hypertension . Patients recruit Department Cardiology university Mainz . There promotion flyer information booklet study cardiologist practicising near Mainz , like send patient study center . Sponsor trial university Mainz . Stefan Blankenberg , MD designate Principal Investigator national , mono-center trial . The study complete last patient last visit telephone follow - two week later perform . This late patient contact define end trial .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Ability provide write informed consent accordance Good Clinical Practice local legislation . Age 35 old . Male female , treated treatmentnaive patient uncontrolled hypertension ( defined 20/10 mmHg target BP &lt; 140/90 mmHg [ &lt; 130/80 mmHg renally impaired and/ diabetic patient ] ) Male female treat patient control hypertension ( define target BP &lt; 140/90 mmHg [ &lt; 130/80 mmHg renally impaired and/ diabetic patient ] ) &gt; 3 cardiovascular risk factor CVRFs and/or metabolic syndrome and/or diabetes mellitus and/or end organ damage 1 . Pretreatment Telmisartan within last 3 month . 2 . Pretreatment Amlodipine , Diuretics AT1Blocker/ACEInhibitor within last 3 month 3 . Myocardial infarction within last 6 month . 4 . Previous stroke hemodynamically relevant stenosis carotic arteria ( &gt; 70 % ) . 5 . Previous cardial peripheral bypass surgery within last 6 month . 6 . PAD stadium III IV n.F . 7 . Chronic heart failure NYHA III IV . 8 . Unstable angina . 9 . Known intolerance angiotensin receptor blocker , diuretic dihydropyridine calcium channel blocker . 10 . Premenopausal woman ( last menstruation ≤1 year prior sign informed consent ) : 1. surgically sterile ; 2. nursing , 3. pregnant , 4. childbearing potential NOT practice acceptable method birth control , NOT plan continue practice acceptable method throughout trial . The acceptable method birth control : 5 . IntraUterine Device ( IUD ) 6 . Oral 7. implantable injectable contraceptive 8 . Estrogen patch 9 . Hormonal birth control use least three month study continue least next menstrual period complete study 11 . Night shift worker routinely sleep daytime whose work hour include midnight 4:00 a.m. 12 . Known suspected secondary hypertension ( e.g. , renal artery stenosis phaeochromocytoma ) 13 . Mean inclinic seat cuff SBP ≥180 mmHg and/or DBP ≥110 mmHg 14 . Renal dysfunction define follow laboratory parameter : 15 . Serum creatinine &gt; 3.0 mg/dL ( &gt; 265 μmol/L ) and/or know estimate creatinine clearance &lt; 30 ml/min and/or clinical marker severe renal impairment . 16 . Bilateral renal artery stenosis , renal artery stenosis solitary kidney , postrenal transplant patient patient one kidney 17 . Clinically relevant hypokalemia hyperkalemia ( i.e. , &lt; 3.0 &gt; 5.5 mEq/L , may rechecked suspected error result ) 18 . Uncorrected sodium volume depletion 19 . Primary aldosteronism 20 . Hereditary fructose intolerance 21 . Biliary obstructive disorder ( e.g. , cholestasis ) hepatic insufficiency 22 . Clinically significant ventricular tachycardia , atrial fibrillation , atrial flutter clinically relevant cardiac arrhythmia determine Investigator 23 . Hypertrophic obstructive cardiomyopathy , severe obstructive coronary artery disease , aortic stenosis , hemodynamically relevant stenosis aortic mitral valve 24 . Patients whose diabetes stable control least past three month define HbA1C ≥10 % 25 . Patients previously experience symptom characteristic angioedema treatment ACE inhibitor angiotensinII receptor antagonist 26 . History drug alcohol abuse within six month prior sign inform consent form 27 . Concomitant administration medication know affect BP , except medication allow protocol 28 . Any investigational drug therapy within one month signing inform consent 29 . Known contraindication component trial drug ( telmisartan , amlodipine , olmesartan , hydrochlorothiazide ) 30 . History noncompliance inability comply prescribed medication protocol procedures 31 . Any clinical condition , opinion investigator , would allow safe completion protocol safe administration trial medication</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>FMD</keyword>
	<keyword>hypertension</keyword>
	<keyword>Telmisartan</keyword>
	<keyword>Amlodipine</keyword>
</DOC>